Results 211 to 220 of about 78,778 (305)
A schematic illustrating the fabrication process and ferroptosis‐mediated therapeutic mechanism of carrier‐free self‐assembled BBR/NC‐SAPs for overcoming bortezomib resistance in multiple myeloma. ABSTRACT Therapeutic relapse driven by bortezomib resistance represents a formidable clinical barrier in the management of multiple myeloma (MM).
Yiwen Lv +16 more
wiley +1 more source
Clinical intramuscular thymus transplantation yields only short‐lived efficacy and marginal therapeutic benefits. Benefiting from the spleen's intrinsic strengths—rapid vascular perfusion, abundant developmental factors, and resident progenitors—the intrasplenic thymic grafts achieve robust thymic regeneration and substantial T‐cell reconstitution ...
Shaocong Wang +10 more
wiley +1 more source
C11-conjugated soft glucocorticoid antibody-drug conjugates for precision immunomodulation. [PDF]
Yaseen AA, Cohen DJ, Zhang A, Tumey LN.
europepmc +1 more source
ABSTRACT Current treatments for immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA), rare autoimmune diseases in which autoreactive B cells play a major role, can lead to high response rates; however, for many patients these responses are not durable or maintained after treatment discontinuation.
Matthieu Mahévas +4 more
wiley +1 more source
HCV-Specific T-Cell Recovery After a Year of SVR Following DAA Therapy. [PDF]
Pozniak T +9 more
europepmc +1 more source
ABSTRACT Objective Given that CD19 chimeric antigen receptor T (CAR‐T) cell therapy frequently induces severe thrombocytopenia and recombinant human thrombopoietin (rhTPO)′s role in managing this CAR‐T‐associated cytopenia remains not well defined, we aimed to evaluate rhTPO's safety and efficacy for treating thrombocytopenia in B‐cell malignancy ...
Jiaqi Guo +10 more
wiley +1 more source
Impact of CD38 Deficiency on B Cell Development in CD19-Deficient Mice. [PDF]
Abrego-Peredo A +6 more
europepmc +1 more source

